Osteoporosis and fracture risk in older people

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 14, Issue 2, 2014, Pages 187-191

  Coughlan, Tara ^a   Dockery, Frances ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GLUCOCORTICOID; PARATHYROID HORMONE; VITAMIN D;

BIOSYNTHESIS; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; CALCIUM BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; EUROPEAN UNION; FRAGILITY FRACTURE; HEALTH CARE SYSTEM; HIP FRACTURE; HUMAN; LONG TERM CARE; MORTALITY; OSTEOBLAST; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SPINE FRACTURE;

ALENDRONATE; BISPHOSPHONATES; BONE MINERAL; CALCIUM; DENSITY; FALLS; FRACTURES; OLDER PEOPLE; OSTEOPOROSIS;

ABSORPTIOMETRY, PHOTON; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; VITAMIN D;

EID: 84898445369     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.14-2-187     Document Type: Review

References (33)

1. Albright F, Bloomberg E, Smith PH. Postmenopausal osteoporosis. Trans Assoc Am Physicians 1940;55:298-305.
2. Fleisch H, Russel RG, Francis MD. Disphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-4.
3. Kanis JA, McCloskey EV, Johansson H et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57.
4. Ensrud KE, Black DM, Palermo L et al. Treatment with alendronate prevents fractures in women at highest risk: results from the fracture intervention trial. Arch Intern Med 1997:155:2617-24. (Pubitemid 27519982)
5. World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994;843:1-129.
6. Siris ES, Chen YT, Abbott TA et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108-12. (Pubitemid 38668990)
7. McCloskey E, Selby P, Davies M et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004;19:728-36. (Pubitemid 41094383)
8. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:18-23. (Pubitemid 36008335)
9. Shepstone L, Fordham R, Lenaghan E et al. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int 2012;23:2507-15.
10. Rabar S, Lau R, O'Flynn N et al. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 2012;345:e3698.
11. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009;339:b4229.
12. Kanis JA, Oden A, Johnell O et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033-46. (Pubitemid 47020000)
13. Bolland MJ, Jackson R, Gamble GD, Grey A. Discrepancies in predicted fracture risk in elderly people. BMJ 2013;346:e8669.
14. Collins GS, Michaëlsson K. Fracture risk assessment: state of the art, methodologically unsound, or poorly reported? Curr Osteoporos Rep 2012;10:199-207.
15. Kanis JA, Oden A, Johansson H, McCloskey E. Pitfalls in the external validation of FRAX. Osteoporos Int 2012;23:423-31.
16. Nguyen ND, Frost SA, Center JR et al. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 2007;18:1109-17. (Pubitemid 47020008)
17. National Institute for Health and Care Excellence. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women, technology appraisal guide 160. London: NICE, 2011.
18. National Osteoporosis Foundation. 2013 clinician's guide to prevention and treatment of osteoporosis. Washington, DC: NOF, 2013.
19. Bolland MJ, Grey A. Disparate outcomes from applying U.K. and U.S. osteoporosis treatment guidelines. J Clin Endocrinol Metab 2010;95:1856-60.
20. Compston J, Cooper A, Cooper C et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009:62:105-8.
21. Bridges MJ, Ruddick S. Ability of FRAX/NOGG guidelines to identify patients sustaining low trauma fractures. Rheumatology (Oxford) 2011:49:391-2.
22. National Institute for Health and Care Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women, technology appraisal guide 161. London: NICE, 2011.
23. Gates BJ, Sonnett TE, Duvall CA, Dobbins EK. Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother 2009;7:293-323.
24. Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012;98:920-5.
25. Abrahamsen B, Sahota O. Do calcium plus vitamin D supplements increase cardiovascular risk? BMJ 2011;342:d2080.
26. National Osteoporosis Society. Vitamin D and bone health: a practical clinical guideline for patient management. London: NOS, 2013.
27. Inderjeeth CA, Poland KE. Management of osteoporosis in older people. J Pharm Pract Res 2010;40:229-34.
28. European Medicines Agency. Recommendation to restrict the use of Protelos/Osseor (strontium ranelate). London: EMA, 2013.
29. National Institute for Health and Care Excellence. Denosumab for the prevention of osteoporotic fractures in postmenopausal women, technology appraisal guidance 204. London: NICE, 2012.
30. Black DM, Reid IR, Boonen S et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243-54.
31. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38. (Pubitemid 46021497)
32. Compston J, Bowring C, Cooper A et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013;75:392-6.
33. Ro C, Cooper O. Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep 2013;11:45-51.